Lehky T J, Levin M C, Kubota R, Bamford R N, Flerlage A N, Soldan S S, Leist T P, Xavier A, White J D, Brown M, Fleisher T A, Top L E, Light S, McFarland H F, Waldmann T A, Jacobson S
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Ann Neurol. 1998 Dec;44(6):942-7. doi: 10.1002/ana.410440613.
Human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disease that results from an interaction of retroviral infection and immune activation. In this study, five doses (1 mg/kg) of humanized anti-Tac antibody were administered to 9 HAM/TSP patients at weeks 0, 2, 6, 10, and 14. Preliminary immunological studies on HAM/TSP patients treated with humanized anti-Tac indicate that there is a selective down-regulation of activated T cells and a decrease in the HTLV-I viral load in peripheral blood lymphocytes, most likely through the selective removal of HTLV-I-infected, activated CD4+ lymphocytes.
人类嗜T淋巴细胞病毒I型（HTLV-I）相关脊髓病/热带痉挛性截瘫（HAM/TSP）是一种由逆转录病毒感染与免疫激活相互作用导致的神经疾病。在本研究中，9例HAM/TSP患者在第0、2、6、10和14周接受了五剂（1mg/kg）人源化抗Tac抗体治疗。对接受人源化抗Tac治疗的HAM/TSP患者进行的初步免疫学研究表明，活化T细胞有选择性下调，外周血淋巴细胞中HTLV-I病毒载量降低，最有可能是通过选择性清除被HTLV-I感染的活化CD4+淋巴细胞实现的。
